Adaptive Biotechnologies Corp insider trading
Every open-market purchase and sale by Adaptive Biotechnologies Corp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Adaptive Biotechnologies Corp’s insiders pay?
From January 29, 2020 to August 28, 2026, 24 insiders reported 0 open-market purchases and 60 sales not made under a pre-set plan in Adaptive Biotechnologies Corp. After sales, the shares moved −13.7% against the index over 12 months (a negative figure means selling was the right call).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Piskel Kyle | Chief Financial Officer | 0 | — | — | 6 | +4.5% (3) | May 20, 2026 |
| Benzeno Sharon | Chief Commercial Ofc Imm Med | 0 | — | — | 5 | −12.4% (3) | March 13, 2026 |
| Lo Francis | Chief People Officer | 0 | — | — | 5 | −12.4% (3) | March 9, 2026 |
| Robins Chad M | CEO and Chairman | 0 | — | — | 5 | +24.6% (2) | August 19, 2026 |
| Adams R Mark | Chief Operating Officer | 0 | — | — | 4 | −44.2% (4) | April 8, 2022 |
| Rubinstein Julie | President and COO | 0 | — | — | 4 | −12.4% (3) | March 6, 2025 |
| Bobulsky Susan | Chief Commercial Officer, MRD | 0 | — | — | 3 | +78.6% (1) | March 13, 2026 |
| Hershberg Robert | Director | 0 | — | — | 3 | +63.0% (1) | August 20, 2026 |
| Robins Harlan S | Chief Scientific Officer | 0 | — | — | 3 | +24.6% (2) | March 13, 2026 |
| Sang Charles | SVP, External Affairs | 0 | — | — | 3 | −61.5% (3) | December 11, 2020 |
| Griffin Michelle Renee | Director | 0 | — | — | 2 | +64.7% (1) | March 13, 2026 |
| Matrix Capital Management Company, LP | Director | 0 | — | — | 2 | −57.8% (2) | March 10, 2021 |
| Neupert Peter M | Director | 0 | — | — | 2 | +63.0% (1) | August 19, 2026 |
| Peterson Tycho | Chief Financial Officer | 0 | — | — | 2 | −79.8% (1) | March 6, 2024 |
| Taylor Stacy L | SVP and General Counsel | 0 | — | — | 2 | −29.4% (1) | March 6, 2024 |
| Baldo Lance | Chief Medical Officer | 0 | — | — | 1 | −29.4% (1) | March 8, 2022 |
| Dobmeier Eric | Director | 0 | — | — | 1 | −43.1% (1) | June 5, 2020 |
| Ott David C. | 10% owner | 0 | — | — | 1 | −61.4% (1) | November 13, 2020 |
| Owen Katey Einterz | Director | 0 | — | — | 1 | — | August 28, 2026 |
| Pellini Michael J | Director | 0 | — | — | 1 | −87.0% (1) | March 3, 2021 |
| Sood Nitin | Chief Commercial Officer, MRD | 0 | — | — | 1 | −54.2% (1) | August 5, 2022 |
| Viking Global Performance LLC and related entities | 10% owner | 0 | — | — | 1 | +68.8% (1) | January 30, 2020 |
| Viking Long Fund Master Ltd. | 10% owner | 0 | — | — | 1 | −74.9% (1) | December 16, 2020 |
| Zoltners Andris A | Director | 0 | — | — | 1 | +64.9% (1) | January 29, 2020 |
When several insiders traded Adaptive Biotechnologies Corp
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Adaptive Biotechnologies Corp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 7 selling crowds, +7.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 4 selling | not yet | not yet | not yet |
| March 31, 2026 | 7 selling | +46.2% | +90.4% | not yet |
| March 31, 2025 | 10 selling | +39.9% | +81.6% | +75.7% |
| March 31, 2023 | 4 selling | −33.2% | −46.4% | −98.4% |
| March 31, 2022 | 8 selling | −24.1% | −28.5% | −29.8% |
| April 30, 2021 | 3 selling | −17.3% | −27.5% | −80.2% |
| December 31, 2020 | 3 selling | −39.6% | −50.3% | −81.3% |
| July 31, 2020 | 3 selling | +37.4% | +34.4% | −37.4% |
← Back to Adaptive Biotechnologies Corp · Funds · Politicians